IPI-549 and Nivolumab: Treating Mesothelioma Patients with Advanced Solid Tumors
Type: Pleural, Peritoneal Mesothelioma
Multimodal therapy has been proven to help improve a mesothelioma patient’s quality of life. In some cases, it can even help them reach a state of remission. Researchers hope that the combination of immunotherapy drug IPI-549 and chemotherapy agent nivolumab will help combat mesothelioma.
Treating Mesothelioma with Chemotherapy and Immunotherapy
A clinical trial sponsored by Infinity Pharmaceuticals, Inc. is combining the use of chemotherapy and immunotherapy in peritoneal and pleural mesothelioma patients that have advanced solid tumors. Participants in the study may have any mesothelioma cell type.
To qualify for this trial, subjects must have attempted first-line chemotherapy and it wasn’t successful in treating their disease. This Phase 1 study anticipates to recruit about 175 enrollees.
- IPI-549 – Is recognized for its ability to inhibit the activity of an enzyme known as P13 kinase. Inhibiting this enzyme is believed to help slow or stop cancer from growing.
- OPDIVO AKA Nivolumab – Works by helping T cells to recognize and attack cancer cells. It blocks the cancer’s ability to disguise itself.
Participants in this clinical trial will be closely evaluated. Researchers will be observing the safety and tolerance of the combination of IPI-549 immunotherapy and intravenous nivolumab.
During this trial, mesothelioma patients will be given IPI-549 orally. They will receive it daily for 28-day cycles.
In addition to IPI-549, patients will also receive nivolumab via IV infusion. Participants will be given doses of nivolumab every two weeks during the 28-day cycles.
Researchers will be collecting data to determine a patient’s overall response rate, duration of response, progression-free survival, and overall survival of the treatment.
Get Help Enrolling in This Trial
Reasons to get involved in this trial include:
- Receive proven life-extending treatment
- Get treated at medical centers that are recognized for their mesothelioma programs
- Multimodal therapies have been proven to help improve a patient’s quality of life
Is This Clinical Trial for You?
Clinical trials provide hope to many mesothelioma patients. They help open the doors to new treatment methods that may improve a patient’s prognosis. In many circumstances, trials offer patients treatment options that they might not have had before.
Researchers take into consideration a patient’s safety when it comes to selecting participants. Here are a few qualifications that may include or omit a patient from this study.
Some Patient Inclusions:
- Confirmed mesothelioma (pleural or peritoneal)
- Subtypes: epithelioid, sarcomatoid, or biphasic
- Progression of disease after experiencing first-line chemotherapy
Some Patient Exclusions:
- Allergic reaction to therapy being used
- Had a major surgery within 4 weeks
- Uncontrolled medical condition
For more information about qualifications for this clinical trial, please contact Mesothelioma Guide’s patient advocate Jenna Campagna. You may reach her at 888-385-2024 extension 102 or email@example.com.
Actively Recruiting at Renowned Mesothelioma Programs
This clinical trial is currently recruiting participants that are a good fit for the study. Some of the facilities hosting this trial are home to nationally recognized mesothelioma programs and specialists.
Some facilities recruiting for this trial are:
- Dana-Farber Cancer Institute (Boston, MA)
- Memorial Sloan Kettering Cancer Center (New York, NY)
- MD Anderson Cancer Center (Houston, TX)
- UCLA (Santa Monica, CA)
These are only some of the locations that are recruiting for this trial. For more information about other facilities and currently recruiting clinical trials, please contact Mesothelioma Guide
Leading the clinical trial is Dr. Claudio Dansky Ullmann. Dr. Ullmann is the Senior Vice President of clinical development at Infinity. He has over 30 years of drug development experience.
Dr. Ullmann’s fields of expertise include head, neck, lung, and melanoma cancers. He has participated in many clinical trials and has researched extensively tumor immunology and drug resistance.